depression and tirzepatide Psychiatric Safety of Tirzepatide: 3 Surprising Findings from a Landmark Post Hoc Analysis of SURMOUNT tirzepatide and antidepressants Mental Health

The most common side effect is mild injection site irritation

The SELECT trial, published in The Lancet (October 22, 2025), provides a landmark analysis confirming that the cardioprotective benefits of semaglutide extend beyond weight loss alone. The SELECT Trial: Study Overview The SELECT trial (NCT03574597) enrolled 17,604 participants aged 45 years and above across 41 countries and 804 sites

By entering a few key details, you'll receive an accurate dose conversion that aligns with best practices in animal care

Smaller portions

However, the clinical relevance of such stratification for predicting treatment response has also been questioned, as it assumes homogeneity within each cluster 8,11,12,13,14

And by injection day, it feels like the tirzepatide weight loss timeline has stalled completely